High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion

Transfusion

Volumn 47, Issue 11, 2007, Pages 1972-1983

  Ziemann, Malte ^a   Krueger, Sabine ^a   Maier, Andrea B ^a   Unmack, Alexander ^a   Goerg, Siegfried ^a   Hennig, Holger ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEOPTERIN; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SENSITIVITY ANALYSIS; SEROCONVERSION; SEROLOGY; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; BLOOD; BLOOD DONORS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MALE; MIDDLE AGED; PREVALENCE; VIREMIA;

EID: 35448968339     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01420.x     Document Type: Article

References (55)

1. Klemola E, Kaariainen L. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br Med 1965 2 : 1099 102.
2. De Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER, Spector SA. Summary of the II International Symposium on cytomegalovirus. Antiviral Res 1998 39 : 141 62.
3. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998 338 : 1741 51.
4. Grigoleit U, Riegler S, Einsele H, Laib SK, Jahn G, Hebart H, Brossart P, Frank F, Sinzger C. Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells. Br J Haematol 2002 119 : 189 98.
5. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006 87 : 1763 79.
6. Larsson S, Söderberg-Naucler C, Moller E. Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals. implications for prevention of CMV transmission. Transplantation 1998 65 : 411 5.
7. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981 98 : 281 7.
8. Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1989 1 : 1228 31.
9. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995 86 : 3598 603.
10. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986 314 : 1006 10.
11. Miller WJ, McCullough J, Balfour HH Jr., Haake RJ, Ramsay NK, Goldman A, Bowman R, Kersey J. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991 7 : 227 34.
12. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion- transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003 101 : 4195 200.
13. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med 2005 19 : 181 99.
14. Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant 1998 22 : 575 7.
15. Narvios AB, Shah H, Lichtiger B. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 2005 36 : 499 501.
16. Dumont LJ, Luka J, VandenBroeke T, Whitley P, Ambruso DR, Elfath MD. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 2001 97 : 3640 7.
17. Drew WL, Tegtmeier G, Alter HJ, Laycock ME, Miner RC, Busch MP. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003 43 : 309 13.
18. Glock B, Schistal E, Mayr WR. CMV DNA in blood donors with IgM and IgG CMV antibodies. Transfusion 2003 43 : 1493 4.
19. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997 64 : 108 13.
20. Jayarama V, Marcello J, Ohagen A, Gibaja V, Lunderville D, Horrigan J, Chapman J, Lazo A. Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents. Transfusion 2006 46 : 1580 8.
21. Brytting M, Xu W, Wahren B, Sundqvist VA. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992 30 : 1937 41.
22. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, Wagner S, Müller CA. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995 86 : 2815 20.
23. Spector SA, Merrill R, Wolf D, Dankner WM. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992 30 : 2359 65.
24. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999 180 : 702 7.
25. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, Wessel K, Kirchner H, Hennig H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000 55 : 178 84.
26. Westermann J, Thiemann F, Gerstner L, Tatzber F, Kozak I, Bertsch T, Kruger C. Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination. Clin Chem Lab Med 2000 38 : 345 53.
27. Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L, Gerna G. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998 177 : 1170 5.
28. Albano MS, Taylor P, Pass RF, Scaradavou A, Ciubotariu R, Carrier C, Dobrila L, Rubinstein P, Stevens CE. Umbilical cord blood transplantation and cytomegalovirus: post-transplant infection and donor screening. Blood 2006 108 : 4275 82.
29. Preiksaitis JK. Prevention of transfusion-acquired CMV infection: is there a role for NAT? Transfusion 2003 43 : 302 5.
30. Boom R, Sol CJ, Schuurman T, Van Breda A, Weel JF, Beld M, Wertheim-Van Dillen PM, De Jong MD. Human cytomegalovirus DNA in plasma and serum specimens of renal transplant recipients is highly fragmented. J Clin Microbiol 2002 40 : 4105 13.
31. Speckner A, Glykofrydes D, Ohlin M, Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol 1999 80 : 2183 91.
32. Larsson S, Söderberg-Naucler C, Wang FZ, Moller E. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion 1998 38 : 271 8.
33. Nitsche A, Steuer N, Schmidt CA, Landt O, Ellerbrok H, Pauli G, Siegert W. Detection of human cytomegalovirus DNA by real-time quantitative PCR. J Clin Microbiol 2000 38 : 2734 7.
34. Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 1995 171 : 1002 6.
35. Roback JD, Drew WL, Laycock ME, Todd D, Hillyer CD, Busch MP. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 2003 43 : 314 21.
36. Roback JD, Hillyer CD, Drew WL, Laycock ME, Luka J, Mocarski ES, Slobedman B, Smith JW, Soderberg-Naucler C, Todd DS, Woxenius S, Busch MP. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 2001 41 : 1249 57.
37. Brinkmann T, Dreier J, Diekmann J, Gotting C, Klauke R, Schumann G, Kleesiek K. Alanine aminotransferase cut-off values for blood donor screening using the new International Federation of Clinical Chemistry reference method at 37 degrees C. Vox Sang 2003 85 : 159 64.
38. Schennach H, Hessenberger G, Mayersbach P, Schönitzer D, Fuchs D. Acute cytomegalovirus infections in blood donors are indicated by increased serum neopterin concentrations. Med Microbiol Immunol 2002 191 : 115 8.
39. Beneke JS, Tegtmeier GE, Alter HJ, Luetkemeyer RB, Solomon R, Bayer WL. Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection. J Infect Dis 1984 150 : 883 8.
40. Lamberson HV Jr., McMillian JA, Weiner LB, Williams ML, Clark DA, McMahon CA, Lentz EB, Higgins AP, Dock NL. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J Infect Dis 1988 157 : 820 3.
41. Ostergaard MS, Ostrem A, Soderstrom M. Hay fever and a single intramuscular injection of corticosteroid: a systematic review. Prim Care Respir J 2005 14 : 124 30.
42. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus- permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997 100 : 3154 63.
43. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997 91 : 119 26.
44. Roback JD, Bray RA, Hillyer CD. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: implications for transfusion transmission of infections. Transfusion 2000 40 : 500 6.
45. Galea G, Urbaniak SJ. Cytomegalovirus studies on blood donors in north-east Scotland and a review of UK data. Vox Sang 1993 64 : 24 30.
46. Hecker M, Qiu D, Marquardt K, Bein G, Hackstein H. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang 2004 86 : 41 4.
47. Ohto H, Ujiie N, Hirai K. Lack of difference in cytomegalovirus transmission via the transfusion of filtered-irradiated and nonfiltered- irradiated blood to newborn infants in an endemic area. Transfusion 1999 39 : 201 5.
48. Murphy MF, Grint PC, Hardiman AE, Lister TA, Waters AH. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. Br J Haematol 1988 70 : 253 4.
49. Bowden RA, Sayers M, Cays M, Slichter SJ. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant. Transfusion 1989 29 (Suppl 57S.
50. de Graan-Hentzen YC, Gratama JW, Mudde GC, Verdonck LF, Houbiers JG, Brand A, Sebens FW, van Loon AM, The TH, Willemze R, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989 29 : 757 60.
51. De Witte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van der Meer JW, Kunst VA. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990 50 : 964 8.
52. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991 78 : 246 50.
53. Eisenfeld L, Silver H, McLaughlin J, Klevjer-Anderson P, Mayo D, Anderson J, Herson V, Krause P, Savidakis J, Lazar A, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992 32 : 205 9.
54. van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994 87 : 144 7.
55. Pamphilon DH, Foot ABM, Adeodu A, Steward CG, Cornish JM, Marks DI, Oakhill A. Prophylaxis and prevention of CMV infection in BM allograft recipients: Leukodepleted platelets are equivalent to those from CMV-seronegative donors. Bone Marrow Transplant 1999 23 (Suppl 1 S66.